Anti Vegf Eylea Hd denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for anti vegf eylea hd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Quantity Limits to Eylea HD

Humana places quantity limits on Eylea HD (high-dose aflibercept) as part of its utilization-management program. These limits define how many doses or units will be covered within a given time period. A quantity-limit denial typically occurs when the prescribing ophthalmologist requests a frequency or total quantity that exceeds Humana's default limit — even when the requested frequency aligns with the FDA-approved dosing regimen in the prescribing label and the individualized treatment plan documented in the chart.

## Why This Denial Is Appealable

Quantity limits are not absolute. Humana's quantity-limit policy is a population-level default; individual patients may have documented clinical reasons — such as persistent disease activity, high lesion burden, or prior inadequate response to less-frequent dosing — that justify a higher frequency. An exception supported by the prescribing ophthalmologist's documented clinical rationale and the FDA-approved labeling is a recognized and viable appeal pathway.

## Federal Appeal Framework

• Quantity-limit exception request: File this simultaneously with or prior to the formal internal appeal; plans often process these under a separate, faster track.
• Internal appeal (ERISA §503 / ACA §2719): Submit within the timeframe on the denial letter.
• External review: Available through an accredited IRO after final internal denial, generally within four months.
• Expedited review: If the patient is actively losing vision and delay would cause irreversible harm, request a 72-hour expedited review in writing with supporting documentation.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's current quantity-limit policy for aflibercept and the FDA-approved prescribing information showing the approved dosing regimen. 2. Compare the requested quantity to the FDA-approved range and confirm the request is within the labeled regimen. 3. Have the ophthalmologist document in the chart — and in a supporting letter — the specific clinical reason the standard quantity is insufficient for this patient. 4. Submit the quantity-limit exception request and internal appeal together with imaging and chart notes. 5. Request expedited review if active disease activity is documented. 6. If denied, pursue external IRO review immediately.

## Documentation to Gather

• FDA prescribing label: The section of the Eylea HD prescribing information that describes the approved dosing schedule — this is the baseline from which the requested quantity should be justified.
• Imaging and clinical notes: OCT and visual-acuity records at each recent visit showing ongoing disease activity that supports the requested frequency.
• Treatment-response history: Documentation that prior dosing intervals resulted in disease recurrence or suboptimal control, with dates and recorded findings.
• Prescriber letter: Explains why the patient's individual clinical course requires the requested quantity, citing chart-documented findings at each visit.
• Humana quantity-limit policy: Obtain the current document to understand the specific limit and any exception criteria.

## Criteria-Mapping Structure

Create a table listing: (1) the quantity limit as stated in Humana's policy; (2) the quantity requested and its basis in the FDA label; and (3) the patient-specific chart evidence — visit dates, imaging findings, visual-acuity measurements — demonstrating why the limit is inadequate. This structure directly addresses the reviewers' framework and presents the exception as a documented clinical necessity rather than a preference.